Fourteen out of 15 severe COVID-19 patients who were treated in an investigator-initiated interventional open-label clinical study of the drug TriCor (fenofibrate) didn’t require oxygen support within a week of treatment and were released from the hospital, according to the results of a new Hebrew University of Jerusalem study.
Fenofibrate is an FDA-approved oral medication. The results were published on Researchsquare.com and are currently under peer review.
Leave a Reply